Intellectual Product
RFK Jr. Faces Bipartisan Senate Criticism After CDC Shakeup
RFK Jr.; CDC shakeup; bipartisan criticism; Senate hearing; public health; vaccine policy; CDC director firing; Trump administration reforms
AstraZeneca Ends Manufacturing License at Indian Plant and Exits Site as Part of Global Strategy
AstraZeneca; India; manufacturing license; site exit; Bangalore plant; contract manufacturing; global strategy; pharmaceutical industry
Paul Offit, RFK Jr. Critic, Removed from Key FDA Vaccine Panel
Paul Offit; FDA; vaccine panel; RFK Jr.; removal; vaccine policy; VRBPAC; advisory committee; HHS
AstraZeneca gears up for FDA filing after baxdrostat’s phase 3 hypertension success
AstraZeneca; baxdrostat; hypertension; FDA filing; aldosterone synthase inhibitor; phase 3 trial; regulatory approval
Vinay Prasad Explains FDA’s Revocation of Pfizer’s Covid Vaccine EUA for Children
FDA; Pfizer; COVID-19 vaccine; emergency use authorization (EUA); children; Vinay Prasad; vaccine policy; risk-benefit analysis
Sanofi Contributes to Report Emphasizing Importance of Sustainably Paid Community Health Workers
Sanofi; community health workers; sustainability; health equity; National Association of Community Health Workers; policy advocacy; digital infrastructure; CHW Access Act
CDC Staff and Medical Organization Liaisons Barred from New ACIP Covid-19 Working Group
CDC; ACIP; Covid-19; working group; staff exclusion; medical groups barred; vaccine policy; Robert F. Kennedy Jr.
Resilience Through Reinvention: How Pharma is Navigating Uncertainty During Turbulent Times
pharma; resilience; reinvention; supply chain; manufacturing uncertainty; regulatory environment; global market adaptation; funding; investment; clinical trials; drug pricing policy; APIs; strategic reserves
Dynavax Highlights Comparable Efficacy and Improved Tolerability of Z-1018 Shingles Vaccine vs. Shingrix
Dynavax; Z-1018; shingles vaccine; Shingrix; vaccine efficacy; side effects; Phase 1/2 trial; immunogenicity
Trump’s Most Favored Nation Policy and EU Generics: Recent Developments
Trump; Most Favored Nation policy; EU generics; drug pricing; tariffs; pharma